🇺🇸 FDA

Company profile · Sponsor

Iovance

Iovance Biotherapeutics B.V.

IOVA · NYSE pharma SAN CARLOS, CA, EU
Pipeline
24
Drugs
1
Patents
8

Quick answer

Iovance (IOVA) is a pharma company. headquartered in SAN CARLOS, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker IOVA
Exchange NYSE
Company type pharma
Headquarters SAN CARLOS, CA, EU
SEC CIK 0001425205

Pipeline (24)

Search pipeline →

  1. Lifileucel plus Pembrolizumab

    Iovance

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  2. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance

    Melanoma

    phase 3 small molecule active

    1 trial

  3. Aldesleukin

    Iovance

    Bone Sarcoma

    phase 2 mab active

    1 trial

  4. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  5. Cyclophosphamide

    Iovance

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  6. Cyclophosphamide

    Iovance

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial

  7. E7 TCR-T cells

    Iovance

    Cervical Cancer

    phase 2 mab active

    1 trial

  8. E7 TCR-T cells

    Iovance

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  9. FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Iovance

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  10. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. IOV-3001

    Iovance

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  12. IOV-4001

    Iovance

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  13. LN-145

    Iovance

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  14. LN-145

    Iovance

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  15. LN-145

    Iovance

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  16. LN-145

    Iovance

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  17. LN-145

    Iovance

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  18. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance

    Neoplasm

    phase 2 small molecule active

    1 trial

  19. Lifileucel

    Iovance

    Endometrial Cancer

    phase 2 mab active

    1 trial

  20. Lifileucel

    Iovance

    Melanoma (Skin Cancer)

    phase 2 mab active

    1 trial

  21. Lifileucel

    Iovance

    Metastatic Melanoma

    phase 2 mab completed

    2 trials

  22. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  23. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Cyclophosphamide

    Iovance

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. lifileucel

    AMTAGVI

    L01XL11

Patents (8)

Search patents →

  1. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Iovance?

Iovance (IOVA) is a pharma company. headquartered in SAN CARLOS, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Iovance sponsor?

We track 24 ClinicalTrials.gov-linked programs for Iovance, including Lifileucel plus Pembrolizumab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Iovance company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.